United Kingdom’s MHRA grants early access to lumasiran a treatment for primary hyperoxaluria type 1 .-Alnylam Pharma

Alnylam Pharmaceuticals, announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted lumasiran, an investigational RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS)

With this decision, eligible PH1 patients in the UK, many of whom are children, can gain access to lumasiran before the drug is granted marketing authorization by the European Commission (EC).